Regeneron Pharmaceuticals...

602.46
2.70 (0.45%)
At close: Apr 25, 2025, 3:59 PM
602.64
0.03%
After-hours: Apr 25, 2025, 05:20 PM EDT

Regeneron Pharmaceuticals Statistics

Share Statistics

Regeneron Pharmaceuticals has 106.95M shares outstanding. The number of shares has increased by -0.79% in one year.

Shares Outstanding 106.95M
Shares Change (YoY) -0.79%
Shares Change (QoQ) -0.52%
Owned by Institutions (%) 86.42%
Shares Floating 104.85M
Failed to Deliver (FTD) Shares 953
FTD / Avg. Volume 0.1%

Short Selling Information

The latest short interest is 2.79M, so 2.54% of the outstanding shares have been sold short.

Short Interest 2.79M
Short % of Shares Out 2.54%
Short % of Float 2.68%
Short Ratio (days to cover) 2.94

Valuation Ratios

The PE ratio is 17.42 and the forward PE ratio is 12.96. Regeneron Pharmaceuticals's PEG ratio is 1.68.

PE Ratio 17.42
Forward PE 12.96
PS Ratio 5.41
Forward PS 3.4
PB Ratio 2.62
P/FCF Ratio 20.97
PEG Ratio 1.68
Financial Ratio History

Enterprise Valuation

Regeneron Pharmaceuticals has an Enterprise Value (EV) of 77.08B.

EV / Sales 5.43
EV / EBITDA 14.49
EV / EBIT 17.44
EV / FCF 21.03

Financial Position

The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.09.

Current Ratio 4.73
Quick Ratio 3.95
Debt / Equity 0.09
Debt / EBITDA 0.51
Debt / FCF 0.74
Interest Coverage 72.3

Financial Efficiency

Return on Equity is 15.03% and Return on Invested Capital is 10.89%.

Return on Equity 15.03%
Return on Assets 11.69%
Return on Invested Capital 10.89%
Revenue Per Employee $940.16K
Profits Per Employee $292.11K
Employee Count 15,106
Asset Turnover 0.38
Inventory Turnover 0.64

Taxes

Income Tax 367.3M
Effective Tax Rate 7.68%

Stock Price Statistics

The stock price has increased by -31.79% in the last 52 weeks. The beta is 0.43, so Regeneron Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.43
52-Week Price Change -31.79%
50-Day Moving Average 644
200-Day Moving Average 851.75
Relative Strength Index (RSI) 50.14
Average Volume (20 Days) 998.6K

Income Statement

In the last 12 months, Regeneron Pharmaceuticals had revenue of 14.2B and earned 4.41B in profits. Earnings per share was 40.9.

Revenue 14.2B
Gross Profit 12.23B
Operating Income 3.99B
Net Income 4.41B
EBITDA 5.32B
EBIT 4.84B
Earnings Per Share (EPS) 40.9
Full Income Statement

Balance Sheet

The company has 2.49B in cash and 2.7B in debt, giving a net cash position of -216.2M.

Cash & Cash Equivalents 2.49B
Total Debt 2.7B
Net Cash -216.2M
Retained Earnings 31.67B
Total Assets 37.76B
Working Capital 26.4B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.42B and capital expenditures -755.9M, giving a free cash flow of 3.66B.

Operating Cash Flow 4.42B
Capital Expenditures -755.9M
Free Cash Flow 3.66B
FCF Per Share 33.96
Full Cash Flow Statement

Margins

Gross margin is 86.13%, with operating and profit margins of 28.1% and 31.07%.

Gross Margin 86.13%
Operating Margin 28.1%
Pretax Margin 33.66%
Profit Margin 31.07%
EBITDA Margin 37.45%
EBIT Margin 28.1%
FCF Margin 25.8%

Dividends & Yields

REGN does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield 5.74%
FCF Yield 4.77%
Dividend Details

Analyst Forecast

The average price target for REGN is $1000, which is 66% higher than the current price. The consensus rating is "Buy".

Price Target $1000
Price Target Difference 66%
Analyst Consensus Buy
Analyst Count 23
Stock Forecasts

Scores

Altman Z-Score 15.08
Piotroski F-Score 6